Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

It's early for RAVR, but the minimally invasive technique has already started gaining momentum as an alternative to both SAVR and TAVR. We spoke to Vinay Badhwar, MD, one of the world’s leading voices in robotic heart surgery, to learn more.

TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.  

Healthcare's ongoing shift toward value-based care is a good thing, Joynt Maddox explained, but its implementation has been far from ideal. She also discussed population health, the pandemic, health disparities and the rising influence of private equity investments.

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Some of the most talked about data at ACC.24 were the results of a late-breaking clinical trial comparing different transcatheter aortic valve replacement (TAVR) valves in patients with a small aortic annulus. 

How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview.